I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).

Mei Wei, Anthony D. Elias, Karthik Giridhar, Matthew P. Goetz, Rita Mukhtar, Christos Vaklavas, Laura van t Veer, Silver Alkhafaji, Gillian L. Hirst, Hope S. Rugo, Nan Chen, W. Fraser Fraser Symmans, Alexander D. Borowsky, Lamorna Brown Swigart, Natsuko Onishi, Douglas Yee, Nola Hylton, Laura Esserman, Jo Chien. I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC). Journal of Clinical Oncology. 2025 Jun 1; 43(16_suppl):612-612.